儿童肺炎支原体肺炎合并肺栓塞9例临床分析并文献复习

doi:10.6040/j.issn.1671-7554.0.2023.0377

摘要/Abstract

摘要： 目的分析儿童肺炎支原体肺炎(MPP)合并肺栓塞(PE)的临床特点及治疗方法。方法回顾性分析2018年1月至2021年12月期间天津市儿童医院呼吸科确诊的9例MPP并发PE患儿的一般资料、临床表现、实验室检查及影像学特点、治疗及预后等病例资料,并进行文献复习。结果 9例MPP合并PE患儿发病年龄3~8岁,中位年龄7.5岁,PE距起病中位时间为14 d。所有患儿均为难治性肺炎支原体肺炎(RMPP),其中胸痛3例、咯血1例、呼吸困难5例,不典型部位放射痛6例;9例患儿CRP、D-二聚体、纤维蛋白原(FIB)均呈不同程度升高,7例患儿PLT计数、IL-6水平升高;9例患儿均筛查血栓性疾病相关指标,其中狼疮抗凝物(LA)阳性5例,抗心磷脂抗体(ACA)阳性5例,抗β2-糖蛋白抗体IgM阳性3例;蛋白S活性降低3例,凝血因子ⅤⅢ升高3例;9例患儿中6例抗核抗体阳性;所有患儿CT肺动脉造影提示栓塞部位充盈缺损,均合并胸腔积液;9例患儿的支气管肺泡灌洗液耐药突变位点2 063/2 064阳性。所有患儿使用利伐沙班序贯低分子肝素抗凝治疗后预后均良好,其中2例合并心脏栓塞者进行溶栓治疗;随访0.5~9个月,9例患儿栓子均缓慢吸收,无血栓复发,自身抗体及血栓性疾病指标恢复正常。结论 MPP合并PE多为RMPP病例,发生PE时间并不一定与疾病极期重合,多数患者会出现一过性自身抗体阳性导致凝血与抗凝纤溶系统失衡;MPP合并PE经及时治疗预后良好,利伐沙班用于儿童肺栓塞具有较好疗效。

关键词: 儿童, 肺炎支原体肺炎, 肺栓塞, 治疗

Abstract: Objective To analyze the clinical characteristics and treatment of mycoplasma pneumoniae pneumonia(MPP)complicated with pulmonary embolism(PE)in children. Methods The general data, clinical manifestations, laboratory tests, imaging features, treatment and prognosis of 9 cases of children with MPP complicated with PE treated during Jan. 2018 and Dec. 2021 were retrospectively analyzed, and relevant literature was reviewed. Results The median age of patients was 3-8 years, with a median of 7.5 years; the median days from onset to PE was 14 days. All cases were refractory MPP(RMPP). Chest pain occurred in 3 cases, hemoptysis in 1 case, dyspnea in 5 cases, and radiating pain at atypical sites in 6 cases. The C-reactive protein(CRP), D-dimer and fibrinogen(FIB)increased in all cases; the platelet(PLT)count and IL-6 levels increased in 7 cases. Screening of thrombophilia-related indexes showed 5 cases of positive lupus anticoagulant(LA), 5 cases of positive anti-cardiolipin antibody(ACA), 3 cases of positive anti-β2-glycoprotein antibody IgM, 3 cases of reduced protein S activity, 3 cases of elevated coagulation factor VIII, and 6 cases of positive antinuclear antibody. CT pulmonary arteriogram showed filling defects at the embolization site with pleural effusion. All cases were positive for bronchoalveolar lavage fluid resistance mutation site 2063/2064. After treatment with sequential low-molecular heparin anticoagulation plus rivaroxaban, all patients recovered well, and 2 children with cardiac embolism received thrombolysis. During the follow-up of 0.5-9 months, all children had slow absorption of emboli, no recurrence occurred, and the autoantibodies and thrombophilia indexes returned to normal. Conclusion MPP complicated with PE is mostly RMPP cases. The onset of PE does not necessarily coincide with the extreme stage of disease. Most patients will have transient autoantibody positivity, leading to imbalance of coagulation and anticoagulation fibrinolytic system. Timely treatment will result in good prognosis, and rivaroxaban is effective in the treatment of the disease.

Key words: Children, Mycoplasma pneumoniae pneumonia, Pulmonary embolism, Treatment

中图分类号:

R725

宋绍秀,徐勇胜. 儿童肺炎支原体肺炎合并肺栓塞9例临床分析并文献复习[J]. 山东大学学报 (医学版), 2023, 61(11): 96-103.

SONG Shaoxiu, XU Yongsheng. Clinical analysis of 9 cases of mycoplasma pneumoniae pneumonia complicated with pulmonary embolism in children and literature review[J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 96-103.

参考文献

[1] Biss TT, Brandao LR, Kahr WH, et al. Clinical features and outcome of pulmonary embolism in children[J]. Br J Haematol, 2008, 142(5): 808-818.
[2] Andrew M, David M, Adams M, et al. Venous thromboembolic complications(VTE)in children: first analyses of the Canadian Registry of VTE[J]. Blood, 1994, 83(5): 1251-1257.
[3] Van Ommen CH, Heijboer H, Buller HR, et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands[J]. J Pediatr, 2001, 139(5): 676-681.
[4] Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey[J]. J Pediatr, 2004, 145(4): 563-565.
[5] Wang Z, Yang L, Ye J, et al. Monocyte subsets study in children with Mycoplasma pneumoniae pneumonia[J]. Immunol Res, 2019, 67(4-5): 373381.
[6] Rodrigues E, Machado A, Silva S, et al. Excess pneumonia and influenza hospitalizations associated with influenza epidemics in Portugal from season 1998/1999 to 2014/2015[J]. Influenza Other Respir Viruses, 2018, 12(1): 153-160.
[7] 中华医学会儿科学分会呼吸组,《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015版)[J]. 中华实用儿科临床杂志, 2015, 30(17): 1304-1308. Respiratory Branch of Chinese Pediatric Society of Chinese Medical Association, Editorial Board of Chinese Journal of Applied Clinical Pediatrics. Expert consensus on diagnosis and treatment of mycoplasma pneumoniae pneumonia in children(2015)[J]. Chinese Journal of Applied Clinical Pediatrics, 2015, 30(17): 1304-1308.
[8] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医学分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组.肺血栓栓塞症诊治与预防指南[J].中华医学杂志, 2018, 98(14): 1060-1087.
[9] Brown SM, Padley S, Bush A, et al. Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors[J]. Pediatr Pulmonol, 2008, 43(2): 200-202.
[10] Graw-Panzer KD, Verma S, Rao S. Venous thrombosis and pulmonary embolism in a child with pneumonia due to Mycoplasma pneumoniae[J]. J Natl Med Assoc, 2009, 101(9): 956-958.
[11] 苏海燕, 金尾静, 张海邻, 等. 支原体肺炎合并肺栓塞一例临床分析[J]. 中华儿科杂志, 2012, 50(2): 151-154. SU Haiyan, JIN Weijing, ZHANG Hailin, et al. Clinical analysis of pulmonary embolism in a child with Mycoplasma pneumoniae pneumonia[J]. Chinese Journal of Pediatrics, 2012, 50(2): 151-154.
[12] Chen Y, Huang P, Chen Q, et al. Two separated thrombi in deep veins associated with pulmonary embolism after Mycoplasma pneumoniae infection: a case in adolescent female[J]. Transl Pediatr, 2013, 2(4): 198201.
[13] 李凤艳, 马威, 谢垒, 等. 肺炎支原体感染致儿童肺梗死一例报告并文献复习[J]. 中国小儿急救医学, 2014, 21(4): 253-254.
[14] 刘燕, 杨晓丽, 高爱梅. 支原体肺炎并肺栓塞、下肢静脉血栓1例临床分析[J]. 山西医科大学学报, 2014, 45(6): 541-542.
[15] 辛毅, 于丽娟, 高兴娟, 等. 儿童肺炎支原体感染合并肺动脉血栓形成一例并文献复习[J]. 中华临床医师杂志(电子版), 2015, 9(8): 1364-1367.
[16] 魏红玲,常艳美,鲁珊.肺炎支原体肺炎合并肺栓塞一例[J]. 中华儿科杂志, 2015, 53(2): 143-144.
[17] Zhuo Z, Li F, Chen X, et al. Mycoplasma pneumonia combined with pulmonary infarction in a child[J]. Int J Clin Exp Med, 2015, 8(1): 1482-1486.
[18] Morichika K, Nakachi S, Tomoyose T, et al. Thromboembolism supervened on Eosinophilia induced by Mycoplasma pneumonia[J]. Intern Med, 2016, 55(18): 2741-2742.
[19] 张凯茹, 李莉, 华静娜. 肺炎支原体感染诱发肺栓塞1例并文献复习[J]. 中国城乡企业卫生, 2018(11): 11-13. doi: 10.16286/j.1003-5052.2018.11.005. ZHANG Kairu, LI Li, HUA Jingna. Pulmonary thromboembolism induced by Mycoplasma pneumomiae: a case report and literature review[J]. Chinese Journal of Urban and Rural Industrial Hygiene, 2018(11): 11-13. doi: 10.16286/j.1003-5052.2018.11.005.
[20] 张晶, 刘奉琴, 郭春艳, 等. 儿童难治性肺炎支原体肺炎合并肺栓塞2例报告[J]. 中国实用儿科杂志, 2019, 34(12): 1043-1045.
[21] 秦嫣然, 王华华, 王燕, 等. 儿童支原体肺炎合并肺栓塞1例报告[J].临床儿科杂志, 2019, 37(10): 765-768. QIN Yanran, WANG Huahua, WANG Yan, et al. Mycoplasma pneumoniae pneumonia complicated with pulmonary embolism in children: a case report[J]. Journal of Clinical Pediatrics, 2019, 37(10): 765-768.
[22] Chen S, Ding Y, Vinturache A, et al. Pulmonary embolism associated with mycoplasma in a child[J]. Lancet Infect Dis, 2020, 20(11): 1347. doi: 10.1016/S1473-3099(20)30253-X.
[23] Saleem S, Berman B. Deep vein thrombosis and pulmonary embolism in the setting of mycoplasma infection[J]. Case Rep Med, 2020: 8708417. doi: 10.1155/2020/8708417.
[24] 黄坤玲, 牛波, 路素坤, 等. 肺炎支原体肺炎并发心腔内血栓、肺栓塞1例并文献复习[J]. 临床儿科杂志, 2021, 39(6): 421-424. HUANG Kunling, NIU Bo, LU Sukun, et al. Mycoplasma pneunomiae pneumonia complicated with cardiac thrombus and pulmonary embolism: a case report and literature review[J]. Journal of Clinical Pediatrics, 2021, 39(6): 421-424.
[25] Kim YS, Lee YY, Lee E. Cases of macrolide-resistant Mycoplasma pneumoniae pneumonia-associated pulmonary thromboembolism[J]. Pediatr Pulmonol, 2021, 56(6): 1796-1799.
[26] Hahn DW, Atkinson CE, Le M. Multiple anatomic sites of infarction in a pediatric patient with M. pneumoniae infection, a case report[J]. BMC Pediatr, 2021, 21(1): 372. doi: 10.1186/s12887-021-02845-3.
[27] 王薇, 常洁, 张晓娟, 等. 儿童重症肺炎支原体肺炎合并肺栓塞的临床分析[J]. 中国药物与临床, 2021, 21(24): 3954-3958.
[28] Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review [J]. Thromb Haemost, 2017, 117(6): 1199-1207.
[29] Narita M. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection[J]. Pediatr Neurol, 2009, 41(3): 159-166.
[30] Witmer CM, Steenhoff AP, Shah SS, et al. Mycoplasma pneumoniae, splenic infarct, and transient antiphospholipid antibodies: a new association?[J]. Pediatrics, 2007, 119(1): e292-e295.
[31] Snowden N, Wilson PB, Longson M, et al. Antiphospholipid antibodies and Mycoplasma pneumoniae infection[J]. Postgrad Med J, 1990, 66(775): 356-362.
[32] Liu J, He R, Wu R, et al. Mycoplasma pneumoniae pneumonia associate thrombosis at Beijing Childrens hospital[J]. BMC Infect Dis, 2020, 20(1): 51. doi: 10.1186/s12879-020-4774-9.
[33] Monagle P. Diagnosis and management of deep venous thrombosis and pulmonary embolism in neonates and children [J]. Semin Thromb Hemost, 2012, 38(7): 683-690.
[34] 孟涛, 王建春. 观察肺炎支原体肺炎患儿血浆内皮素和抗凝血酶-Ⅲ的变化[J]. 实用医技杂志, 2006, 13(1): 39-40.
[35] Creagh MD, Roberts IF, Clark DJ, et al. Familial antithrombin III deficiency and Mycoplasma pneumoniae pneumonia [J]. J Clin Pathol, 1991, 44(10): 870-871.
[36] Pachet A, Dumestre-Perard C, Moine M, et al. Splenic infarction associated with transient anti-prothrombin antibodies is a rare manifestation of acute Mycoplasma pneumoniae infection [J]. Arch Pediatr, 2019, 26(8): 483-486.
[37] Margetic S. Inflammation and hemostasis [J]. Biochem Med, 2012, 22(1): 49-62.
[38] Flateau C, Asfalou I, Deman AL, et al. Aortic thrombus and multiple embolisms during a Mycoplasma pneumoniae infection [J]. Infection, 2013, 41(4): 867-873.
[39] Biss TT, Rajpurkar M, Williams S, et al. Recommendations for future research in relation to pediatric pulmonary embolism: communication from the SSC of the ISTH [J]. J Thromb Haemost, 2018, 16(2): 405-408.
[40] Moore AJE, Wachsmann J, Chamarthy MR, et al. Imaging of acute pulmonary embolism: an update [J]. Cardiovasc Diagn Ther, 2018, 8(3): 225-243.
[41] Obeng EA, Harney KM, Moniz T, et al. Pediatric heparin induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system [J]. J Pediatr, 2015, 166(1): 144-150.
[42] Young G. Anticoagulation therapies in children [J]. Pediatr Clin North Am, 2017, 64(6): 1257-1269.
[43] Male C, Lensing AWA, Palumbo Joseph S, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial [J]. Lancet Haematol, 2020, 7(1): e18-e27.
[44] 孙雨茁, 罗平. 利伐沙班在儿童血栓栓塞性疾病的应用研究进展[J]. 中华实用儿科临床杂志, 2022, 37(9): 710-713. SUN Yuzhuo, LUO Ping. Advances in applied research of Rivaroxaban in children with thromboembolic disease [J]. Chinese Journal of Applied Clinical Pediatrics, 2022, 37(9): 710-713.
[45] Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venou thromboembolism [J]. Blood Adv, 2018, 2(22): 3292-3316.
[46] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J]. Chest, 2012, 141(2 Suppl): e737S-e801S.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed